PerpetualMeds

Perpetual Medicines is a fully integrated computational peptide therapeutics company building a next-generation peptide drug discovery engine. The company's platform combines leading-edge computational physics methods — including free energy perturbation (FEP) and quantum chemistry — with next-generation AI technologies and advanced synthetic chemistry to access vast, unexplored peptide chemical space. The platform is designed to address previously undruggable targets, accelerate drug discovery, and enhance the quality of peptide drug candidates. Founded in March 2023, the company has operations in Shanghai, China and Boston, MA, and completed an $8 million Seed round in November 2023. In July 2025, Perpetual Medicines announced a strategic merger with TandemAI to expand physics- and AI-based drug discovery capabilities.